Alefacept (CAT#: TP-089CL)
Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD.
Specific Inquiry
Specifications
- Classify
- Protein therapeutics that interfere with a molecule or organism: Immunoregulation
- Therapeutic
- Alefacept
- Trade Name
- Amevive
- Function
- Dimeric fusion protein that binds cD2 on the surface of lymphocytes and inhibits interaction with LFA3; this association is important for the activation of T lymphocytes in psoriasis
- Examples of clinical use
- Adults with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy
References
- Synonyms
- ASP0485
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
Customer Reviews and Q&As
There are currently no Customer reviews or questions for TP-089CL. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.